Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET: JNJ-64304500 add-on therapy in active Crohn's disease responders not in remission
jRCT2031200406Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of NNC0142-0002 in Crohn's disease (4 arms), sponsored by Janssen Pharmaceutical. Started Mar 2021; status: completed.
02
Drugs
NNC0142-0002
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2031200406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200406.